Skip to content

Released Nov 13, 2025, before the open

10-Q filed Nov 13, 2025, 44 days after period end · 0001104659-25-110824

Q3 2025 · 10-Q
Revenue$17.85M−0.6% vs Q3 2024+14.0% vs Q2 2025
Net Income$2.36M−27.2% vs Q3 2024+1,336.0% vs Q2 2025
EPS Diluted$0.03±0.0% vs Q3 2024no prior Q2 2025 on file
Operating Income$2,131,000−46.6%
Operating Cash Flowderived-$3,732,000N/M
Free Cash Flowderived-$4,230,000N/M
Margins · derived
Operating margin11.9%−10.3 pt vs Q3 2024
Net margin13.2%−4.8 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$17.85M$17.96M$10.35M$14.18M
Net Income$2.36M$3.24M-$1.85M-$3.57M
EPS Diluted$0.03$0.03-$0.04-$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR